Browse 122 retinitis pigmentosa clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Retinitis pigmentosa usually begins with trouble seeing at night and slowly narrows side vision, and more than 100 genes have been linked to it. The eye was the site of a medical first: in 2017 the FDA approved its first gene therapy for an inherited disease, for vision loss caused by one of those genes. Most people with retinitis pigmentosa have a different gene change and still no approved treatment. Gene therapies, cell therapies, and treatments that work regardless of the gene are now in trials, and genetic testing is the first step toward them.
Collection and Storage of Human Biospecimens for Research Into Rare Diseases and Medical Conditions
for
Rare Genetic Disorders
Location: Chicago IL
Sponsor: BioMarin Pharmaceutical
Sex: All
Age: 0+
Code: NCT02365376
Recruiting
The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis
for
Glaucoma, Eye Diseases, Cornea Disease
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Sex: All
Age: 18 - 70+
Code: NCT04232982
Recruiting
Impact of COVID-19 on Quality of Life of Seniors With Eye Disease and Implementations to Improve Wellness
for
Covid19, Eye Diseases
Location: London
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sex: All
Age: 65+
Code: NCT04910282
Recruiting
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
for
Radiation Retinopathy, Visual Impairment
Location: Boston MA, Manchester CT, Philadelphia PA, Durham NC,
Sponsor: Jaeb Center for Health Research
Sex: All
Age: 18+
Code: NCT05844982
Phase 3, Recruiting
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
for
Ocular Hyperemia
Location: Newport Beach CA, Los Angeles CA
Sponsor: Alcon Research
Sex: All
Age: 18+
Code: NCT07531043
Phase 3, Recruiting
An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults
Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency